Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study

被引：0
|
作者：
Buisson, A. [1 ]
Jammet, A. [1 ]
Pereira, B. [2 ]
Fumery, M. [3 ]
机构：
[1] CHU Clermont Ferrand, IBD Unit, Clermont Ferrand, France
[2] CHU Clermont Ferrand, Biostat Unit, Clermont Ferrand, France
[3] CHU Amiens, IBD Unit, Amiens, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P435
引用
收藏
页码：562 / 564
页数：3
相关论文
共 50 条
  • [1] REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND A SECOND ANTI-TNF AGENT IN PATIENTS WITH SYMPTOMATIC STENOSING CROHN'S DISEASE AFTER FAILURE OF A FIRST ANTI-TNF AGENT: RESULTS OF THE USTEKNOSIS STUDY
    Buisson, Anthony
    Jammet, Arthur
    Pereira, Bruno
    Fumery, Mathurin
    GASTROENTEROLOGY, 2023, 164 (06) : S648 - S648
  • [2] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
    Cassandra Rayer
    Maria Nachury
    Arnaud Bourreille
    Xavier Roblin
    Laurent Peyrin-Biroulet
    Stephanie Viennot
    Mathurin Flamant
    David Laharie
    Bénédicte Caron
    Marie Dewitte
    Laurent Siproudhis
    Mathurin Fumery
    Guillaume Bouguen
    BMC Gastroenterology, 22
  • [3] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study
    Cassandra, Rayer
    Nachury, Maria
    Arnaud, Bourreille
    Xavier, Roblin
    Laurent, Peyrin-Biroulet
    Stephanie, Viennot
    Mathurin, Flamant
    David, Laharie
    Benedicte, Caron
    Marie, Dewitte
    Laurent, Siproudhis
    Mathurin, Fumery
    Guillaume, Bouguen
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [4] Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
    Cassandra Rayer
    Maria Nachury
    Arnaud Bourreille
    Xavier Roblin
    Laurent Peyrin-Biroulet
    Stephanie Viennot
    Mathurin Flamant
    David Laharie
    Bénédicte Caron
    Marie Dewitte
    Laurent Siproudhis
    Mathurin Fumery
    Guillaume Bouguen
    BMC Gastroenterology, 23
  • [5] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study(vol 22, 498, 2022)
    Rayer, Cassandra
    Nachury, Maria
    Bourreille, Arnaud
    Roblin, Xavier
    Peyrin-Biroulet, Laurent
    Viennot, Stephanie
    Flamant, Mathurin
    Laharie, David
    Caron, Benedicte
    Dewitte, Marie
    Siproudhis, Laurent
    Fumery, Mathurin
    Bouguen, Guillaume
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [6] Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent
    del Carmen R-Grau, Maria
    Chaparro, Maria
    Mesonero, Francisco
    Barreiro-de Acosta, Manuel
    Castro, Luisa
    Castro, Manuel
    Domenech, Eugeni
    Mancenido, Noemi
    Lazaro Perez-Calle, Jose
    Taxonera, Carlos
    Barrio, Jesus
    De Francisco, Ruth
    Fernandez-Salgado, Estela
    Luzon, Lara
    Merino, Olga
    Oltra, Lorena
    Saro, Cristina
    Bermejo, Fernando
    Garcia-Sanchez, Valle
    Ginard, Daniel
    Gutierrez, Ana
    Vera, Isabel
    Anton, Rosario
    Ber, Yolanda
    Calvet, Xavier
    Gisbert, Javier P.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 613 - 619
  • [7] Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent
    Fumery, Mathurin
    Serrero, Melanie
    Bouguen, Guillaume
    Amiot, Aurelien
    Altwegg, Romain
    Nachury, Maria
    Vuitton, Lucine
    Treton, Xavier
    Caillo, Ludovic
    Pereira, Bruno
    Buisson, Antony
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (10): : 1615 - 1621
  • [8] Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn's Disease After Failure of Anti-TNF Agents: Real-World Evidence
    Alamer, A.
    Al Lehaibi, L.
    Alomar, M.
    Aldhuwayan, F.
    Alshouish, S.
    Al-Ali, A.
    Almudhry, Z.
    Almulhim, A.
    Althagafi, A.
    Aldosari, S.
    Alameel, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1297 - I1297
  • [9] Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
    Buisson, A.
    Serrero, M.
    Altwegg, R.
    Guilmoteau, T.
    Bouguen, G.
    Nachury, M.
    Amiot, A.
    Vuitton, L.
    Treton, X.
    Caillo, L.
    Pereira, B.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 707 - 707
  • [10] REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: RESULTS FROM THE TORUS STUDY
    Buisson, Anthony
    Serrero, Melanie
    Altwegg, Romain
    Guilmoteau, Thomas
    Guillaume, Bouguen
    Nachury, Maria
    Amiot, Aurelien
    Vuitton, Lucine
    Treton, Xavier
    Caillo, Ludovic
    Pereira, Bruno
    Fumery, Mathurin
    GASTROENTEROLOGY, 2023, 164 (06) : S4 - S4
12345